AXA bought a new position in Bioverativ Inc (NASDAQ:BIVV) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 224,478 shares of the biotechnology company’s stock, valued at approximately $12,811,000. AXA owned about 0.21% of Bioverativ at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of BIVV. Advisors Asset Management Inc. bought a new position in shares of Bioverativ in the third quarter valued at approximately $137,000. TCI Wealth Advisors Inc. bought a new position in shares of Bioverativ in the third quarter valued at approximately $186,000. Ladenburg Thalmann Financial Services Inc. bought a new position in shares of Bioverativ in the third quarter valued at approximately $190,000. Canada Pension Plan Investment Board bought a new position in shares of Bioverativ in the third quarter valued at approximately $194,000. Finally, ACG Wealth bought a new position in shares of Bioverativ in the third quarter valued at approximately $205,000. Hedge funds and other institutional investors own 95.99% of the company’s stock.
Shares of Bioverativ Inc (NASDAQ BIVV) traded up $1.04 during trading hours on Friday, reaching $63.75. 1,560,000 shares of the company were exchanged, compared to its average volume of 1,110,000. The company has a market capitalization of $6,900.00 and a PE ratio of 15.59. Bioverativ Inc has a 1 year low of $40.00 and a 1 year high of $64.68.
Bioverativ (NASDAQ:BIVV) last issued its quarterly earnings results on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.25. The business had revenue of $291.60 million during the quarter, compared to the consensus estimate of $285.45 million. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The business’s revenue for the quarter was up 27.2% on a year-over-year basis. analysts expect that Bioverativ Inc will post 2.48 EPS for the current year.
Several research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Bioverativ from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Morgan Stanley reiterated an “underweight” rating and issued a $47.00 price objective (up from $45.00) on shares of Bioverativ in a report on Friday, October 6th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $71.00 price objective on shares of Bioverativ in a report on Monday, October 23rd. Royal Bank of Canada initiated coverage on shares of Bioverativ in a report on Thursday, September 14th. They issued a “sector perform” rating and a $59.00 price objective for the company. Finally, Argus upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 target price for the company in a report on Wednesday, September 20th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $60.47.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.